11:00 Chairperson’s Opening
Paul Kosnik, Vice President, Clinical Development, Orgenesis

11:05 The Promise of Regenerative Medicine 

• Has the promise of regenerative medicine been fulfilled?
• What are the challenges of repairing damaged organs and tissues?
• How do we design optimal regenerative medicine products?

Ian McNiece, Chief Executive Officer, Biocardia

11:20 STOP AND RETHINK! Don’t Settle with a Narrow Cell Viability Window; Take Back Stability Control of Your Cell Therapy

• How to improve viability of a range of different cell types post-cryopreservation
• Hypothermic storage of MSC´s and considerations for extended cell viability at room temperature

Phil Morton, Chief Technology Officer, Albumedix Ltd.

11:35 Continuous Progress in C&GT: Professionalizing Cells for Therapeutic Objectives

• Cell therapy needs to continue optimization from sourcing to therapeutic effect
• MSCs have delivered some effect in several indications and their therapeutic effect can be optimized
• The sourcing and manufacturing of MSCs for allogeneic use continues to represent an opportunity that can be enhanced

Anthony Ting, Chief Scientific Officer, Bone Therapeutics

11:50 Clinical Testing of an Extracellular Vesicle Biologic

• Introduction to perinatal extracellular vesicles
• Novel mechanisms of immune and inflammatory modulation
• Update on ongoing clinical trials with perinatal extracellular vesicles

Mari Mitrani, Chief Scientific Officer, Organicell Regenerative Medicine

12:05 Speaker Q&A and Panel Discussion